GlassScriptPhysician profile
Michelle A Rojas
NPI 1205806718
$6,404.31
in general payments reported to CMS, 2019-2025
35 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $724 · 2021: $1,375 · 2022: $695 · 2023: $805 · 2024: $893 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,312.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,193.09 | 2019-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $894.03 | 2019-2024 | |
| Novo Nordisk INC | $689.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $532.82 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $296.04 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $291.70 | 2019-2023 | |
| Lilly USA, LLC | $273.83 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Insulet Corporation | $249.35 | 2021-2023 | Omnipod |
| Abbvie INC. | $228.23 | 2021-2025 | Ubrelvy, Qulipta |
| Abbott Laboratories | $188.98 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $172.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $154.56 | 2021-2024 | |
| Amgen INC. | $148.34 | 2019-2025 | Otezla, Repatha |
| Janssen Biotech, INC. | $134.89 | 2019-2023 | Symtuza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.83 | 2019-2024 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $97.73 | 2019-2021 | |
| Astellas Pharma US INC | $83.86 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.75 | 2019-2023 | Trulance, Xifaxan |
| Renalytix Ai, INC. | $72.81 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Alnylam Pharmaceuticals INC. | $69.19 | 2022-2025 | Onpattro |
| Glaxosmithkline, LLC. | $62.77 | 2021-2023 | Pediarix, Bexsero |
| Forte Bio-Pharma LLC | $53.95 | 2020 | |
| Dexcom, INC. | $52.25 | 2023 | Dexcom G6 Transmitter |
| Napo Pharmaceuticals INC | $41.15 | 2019 | |
| Exact Sciences Corporation | $39.07 | 2023-2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $28.08 | 2020-2021 | |
| Braeburn INC. | $19.64 | 2023 | Brixadi |
| Indivior INC. | $18.69 | 2024 | Sublocade |
| Sunovion Pharmaceuticals INC. | $17.72 | 2020 | |
| Theratechnologies INC. | $15.67 | 2020 | |
| Azurity Pharmaceuticals, INC. | $15.21 | 2023 | Adthyza |
| Biohaven Pharmaceutical Holding Company LTD. | $14.69 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.34 | 2019 | |
| Eisai INC. | $14.12 | 2021 | |
| Currax Pharmaceuticals LLC | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.